2026 -- H 8360 | |
======== | |
LC006206 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2026 | |
____________ | |
A N A C T | |
RELATING TO COMMERCIAL LAW -- GENERAL REGULATORY PROVISIONS -- | |
DECEPTIVE TRADE PRACTICES | |
| |
Introduced By: Representatives Ackerman, Donovan, McNamara, Fellela, Edwards, | |
Date Introduced: March 27, 2026 | |
Referred To: House Corporations | |
(Attorney General) | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Chapter 6-13.1 of the General Laws entitled "Deceptive Trade Practices" is |
2 | hereby amended by adding thereto the following section: |
3 | 6-13.1-31. Prohibited acts - Pharmacy benefits managers. |
4 | (a) For the purposes of this section: |
5 | (1) “Effective rate pricing” means any payment reduction for pharmacist or pharmacy |
6 | services by a pharmacy benefits manager through reconciliation processes or aggregate payment |
7 | reductions that are not expressly disclosed and agreed to between the pharmacy benefits manager |
8 | and pharmacist or pharmacy and that result in reimbursement below the contracted rate. |
9 | (2) “Enrollee” means an individual residing in this state for whom an insurer administers, |
10 | provides, pays for, insures, or covers healthcare services; provided, however, that for purposes of |
11 | this section, the term shall exclude individuals enrolled in Medicare Part D, the federal employee |
12 | health benefit program, TRICARE, or the VA program. |
13 | (3) “Inducement” means a financial incentive including, but not limited to, variations in |
14 | premiums, deductibles, copayments, or coinsurance, offered to influence the selection, |
15 | recommendation, or use of health care items or services. |
16 | (4) “Maximum allowable cost price” or “MAC price” means the maximum amount that a |
17 | pharmacy benefits manager will reimburse toward the cost of a drug. |
18 | (5) “Patient steering” means any communication, verbal or written, by a pharmacy benefits |
| |
1 | manager to a patient to directly or indirectly influence the patient’s choice of pharmacy or |
2 | encourage use of an alternate pharmacy that is a preferred pharmacy. This includes any requirement |
3 | that a consumer utilize a particular pharmacy. |
4 | (6) “Pharmacy benefits manager” or “PBM” means an entity doing business in this state |
5 | that contracts to administer or manage prescription drug benefits on behalf of any carrier that |
6 | provides prescription drug benefits to residents of this state. |
7 | (7) “Spread pricing” means the model of prescription drug pricing in which a pharmacy |
8 | benefits manager charges a health benefit plan a contracted price for prescription drugs that differs |
9 | from the amount the pharmacy benefits manager directly or indirectly pays the pharmacist or |
10 | pharmacy for pharmacy goods or services. |
11 | (b) Violations. It shall be an unfair and deceptive trade practice and a method of unfair |
12 | competition in violation of this chapter for any pharmacy benefits manager to: |
13 | (1) Conduct or participate in spread pricing or effective rate pricing; |
14 | (2) Directly or indirectly engage in patient steering to a pharmacy in which the pharmacy |
15 | benefits manager, or any of its affiliated entities, maintains an ownership interest or control; |
16 | (3) Penalize an enrollee or offer an inducement to an enrollee for the purpose of |
17 | encouraging use of a specific retail, mail-order, or other pharmacy in which a pharmacy benefits |
18 | manager holds an ownership or controlling interest, or in which the pharmacy holds an ownership |
19 | or controlling interest in the pharmacy benefits manager; |
20 | (4) Require a pharmacist or pharmacy to purchase drugs from a particular wholesaler; |
21 | (5) Deflate or fail to adjust the MAC price set by the pharmacy benefits manager where the |
22 | wholesaler offering the price upon which the MAC price is based chooses not to sell the drug to |
23 | the pharmacist or pharmacy, rendering the MAC price unavailable to the pharmacist or pharmacy; |
24 | (6) Fail to honor maximum allowable cost requirements in accordance with §§ 27-18-33.2, |
25 | 27-19-26.2, 27-20-23.2, 27-20.1-15.1, or 27-41-38.2; |
26 | (7) Impose an early-refill restriction on a maintenance medication with a prescription of at |
27 | least a thirty (30) day supply that requires fewer than seven (7) days of medication remaining before |
28 | the prescription may be refilled; provided, however, that pursuant to regulation, guidance or at the |
29 | direction of the executive office of health and human services, a pharmacy benefits manager may |
30 | apply a more restrictive early refill policy for Medicaid enrollees without violating the provisions |
31 | of this subsection. This provision shall not apply to controlled substances in schedules II to V; |
32 | (8) Fail to honor or otherwise delay the acceptance of previously completed step therapy |
33 | documentation where the prescribed drug is on the health plan’s prescription drug formulary, the |
34 | enrollee has tried the step therapy required while enrolled in their current health plan or a health |
| LC006206 - Page 2 of 5 |
1 | plan in which they were previously enrolled, and the enrollee’s provider has submitted justification |
2 | and supporting clinical documentation that such prescription drug was discontinued due to lack of |
3 | efficacy or effectiveness, diminished effect, or an adverse effect or event; |
4 | (9) Exploit prescription drug information obtained from enrollees for monetary gain or |
5 | economic power over pharmacists or pharmacies including, but not limited to, using data mining |
6 | or other similar methods to gather patient information generated or obtained throughout the |
7 | prescription filling process at any pharmacy for the purpose of directing business toward a |
8 | pharmacy commonly owned, controlled, or exclusively contracted with the PBM; |
9 | (10) Sell, exchange, or use in any manner prescription drug information regarding an |
10 | enrollee obtained from an enrollee’s use of a prescription drug for purposes of marketing |
11 | solicitation, patient steering, generating referrals, or any other practice or act that provides the |
12 | pharmacy benefits manager, or any of its affiliates or subsidiaries, economic power or control over |
13 | pharmacists or pharmacies, or that interferes in the enrollee’s free choice of pharmacy; |
14 | (11) Engage in drug repackaging for the purpose of extracting a price markup. A pharmacy |
15 | benefits manager that owns or controls a mail-order pharmacy shall not allow the mail-order |
16 | pharmacy to repackage drugs for the purpose of selling the repackaged items at prices higher than |
17 | the reimbursement price of the drug in its original manufacturer packaging, unless the enrollee to |
18 | whom the repackaged drugs are dispensed is informed in writing that the drug has been repackaged |
19 | and is being sold at a higher price; or |
20 | (12) Operate in Rhode Island without being registered and in good standing with the |
21 | secretary of state to do business in the state or without being licensed and in good standing with the |
22 | department of business regulation. Each day that a pharmacy benefits manager operates without |
23 | such registration or licensure and good standing shall constitute a separate violation. |
24 | (c) Construction. |
25 | (1) Except where expressly provided, for purposes of this section, a violation shall be |
26 | deemed to occur each time a prohibited act is committed for each individual consumer transaction. |
27 | (2) Nothing in this section shall be construed to prohibit truthful, non-misleading |
28 | communications regarding cost or interfere with, or violate, a consumer’s right to know where the |
29 | consumer may obtain the lowest cost drugs, whether a consumer is utilizing insurance or other |
30 | third-party reimbursement or not. |
31 | (3) Nothing in this section shall be construed to interfere with the requirement that |
32 | consumers receive notice of changes to pharmacy networks, such as the inclusion of new |
33 | pharmacies or removal of existing pharmacies from networks. |
34 | (4) Nothing in this section shall prohibit the authorized use of protected health information |
| LC006206 - Page 3 of 5 |
1 | for health care operations under the Health Insurance Portability and Accountability Act of 1996 |
2 | (Pub. L. No. 104-191). |
3 | (5) Nothing in this section shall be construed or applied in a manner that conflicts with |
4 | applicable federal law or regulation. |
5 | (6) Nothing in this section shall be construed to limit or preclude the authority of the |
6 | attorney general to pursue any other remedy, penalty, or cause of action available under common |
7 | law or statute including, but not limited to, actions for injunctive relief, restitution, civil penalties, |
8 | or other equitable or legal relief. Nor shall this section be construed to limit the application of |
9 | chapter 13.1 of title 6 ("deceptive trade practices") or any other provision of the general laws to the |
10 | conduct described herein. This amendment shall be interpreted to clarify existing law only. |
11 | SECTION 2. This act shall take effect upon passage. |
======== | |
LC006206 | |
======== | |
| LC006206 - Page 4 of 5 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO COMMERCIAL LAW -- GENERAL REGULATORY PROVISIONS -- | |
DECEPTIVE TRADE PRACTICES | |
*** | |
1 | This act would provide that certain actions taken by pharmacy benefits managers are to be |
2 | considered deceptive or unfair trade practices. |
3 | This act would take effect upon passage. |
======== | |
LC006206 | |
======== | |
| LC006206 - Page 5 of 5 |